Epidemiology and Genomics Research
CANCER EPIDEMIOLOGY MATTERS E-NEWS
JULY 2017

Follow us on Twitter
July 2017 Features
Announcements
Contact Us
FOAsFunding
 Opportunity Announcements
 
RFA-ES-17-006  (U01)
Expanding Genome Integrity Assays to Population Studies 
Applications due: October 13, 2017
Expiration date: October 14, 2017

HHS Small Business Innovation Research (SBIR) Program Contract Solicitation (PHS 2018-1) Now Available
Pre-proposal webinar: August 15, 2017
Applications due: October 20, 2017

RFA-HG-17-011  (U24)*
The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL)
Applications due: November 9, 2017
Expiration date: November 10, 2017

PA-17-325 (R01)
PA-17-323 (R21)
PA-17-324 (R03)
Ethical, Legal, and Social Implications (ELSI) of Genomics

Applications Due: Standard dates apply
Expiration Date: September 8, 2020

* NCI is not participating in these funding opportunities.
PolicyGrants Policy Announcements
Revision: Guidance on Salary Limitation for Grants and Cooperative Agreements
  Applications due August 25, 2017
JobJob Opportunities
 

EventsUpcoming Webinars & Workshops
Guiding Principles for Developing Dietary Reference Intakes Based on Chronic Disease - Report Release
August 3, 2017

September 25-26, 2017
Rockville, MD

September 27, 2017

October 3, 2017

October 11, 2017

October 18, 2017

October 25-27, 2017
Baltimore, MD

October 31, 2017

SAVE-THE-DATE: NCI Cohort Consortium Annual Meeting
November 13-14, 2017
Rockville, MD

Breast Cancer and the Environment Research Program Annual Meeting
November 16-17, 2017
Monrovia, CA
Note: View call for abstracts for oral and poster presentations. Deadline to submit abstracts is September 1, 2017. View submission instructions

Conference on the Science of Dissemination and Implementation in Health
December 4-6, 2017
Arlington, VA

NIH Pathways to Prevention Workshop: Methods for Evaluating Natural Experiments in Obesity
December 5-6, 2017
Bethesda, MD
Note: Abstracts for the poster session are being accepted. Submissions due by August 31, 2017. 
BlogsBlog Posts
Sanya Springfield, Ph.D.
NCI Cancer Currents Blog
 

Improving Cancer Control in Rural Communities: Next Steps
Robert Croyle, Ph.D.
NCI Cancer Currents Blog
 
Elizabeth Kittrie, M.S.M.
DataScience@NIH Blog

Katrina I. Theisz, M.S.
DataScience@NIH Blog
AboutAbout EGRP
The Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) funds research in human populations to understand the causes of cancer and related outcomes.

The Program fosters interdisciplinary collaborations, as well as the development and use of resources and technologies to advance cancer research and translation of this research, which serve as the basis for clinical and public health interventions.
ContactContact Us
email: nciepimatters@mail.nih.gov
website: epi.grants.cancer.gov
twitter: twitter.com/NCIEpi
FAQs
Frequently Asked Questions Related to Submitting Grant Applications


Scientific staff in the Epidemiology and Genomics Research Program (EGRP) have a number of responsibilities, one of which is to help investigators who are planning to submit grant applications understand NCI and NIH pre-submission policies and procedures.

Investigators who have questions that they have had difficulty finding the answers to frequently contact EGRP staff for assistance. Examples of some commonly asked questions are listed below:

How can I tell if NIH considers me an Early Stage Investigator (ESI)? View NIH definition of ESI 

Can I submit an application under an NIH Funding Opportunity Announcement (e.g., a Program Announcement or Request for Applications) if I've already submitted an investigator-initiated application to NIH and it is currently pending review? View answer

I received a notice that my application will be undergoing a second level of review by the National Cancer Advisory Board (NCAB). What does this review entail? If my application is approved by the NCAB, does this mean my application will be funded? View answer

How do I request an Institute/Center or study section assignment for my incoming grant application? View answer

I'm planning on submitting a P01 grant application and I'm a member of a standing NIH Study Section. Is my application eligible for continuous submission? View answer

As a non-appointed temporary member of an NIH Study Section, am I eligible to submit my application under the continuous submission policy? View answer

I have a co-investigator on my application who is a regular member of a chartered NIH Study Section. Is my application eligible for continuous submission? View answer

Answers to all of the above questions (and many others) are available through this EGRP webpage, which contains links to FAQs related to grant mechanisms for new and early stage investigators and research projects with multiple principal investigators, as well as more general information about NIH grant application preparation, submission, and tracking. 

We also encourage you to explore the grantsmanship resources section of EGRP's website for links to more information about the  peer review process, award management reporting, and more. 

Additionally, EGRP staff are always available to answer your questions about the submission process. Investigators who do not currently have an assigned program director are invited to review the EGRP staff list to identify staff with relevant scientific interests to contact.
Moonshot
Upcoming Cancer Moonshot Funding Opportunities

In response to recommendations provided in the Blue Ribbon Panel report, NCI established implementation teams to consider multiple ways to fund Cancer Moonshot-related research. These teams have identified nine upcoming scientific opportunities that directly address the goals of the Cancer Moonshot:
These funding opportunities are expected to be formally released in the coming months and awards are expected to be made pending the appropriation of the 2018 fiscal year funding for the Cancer Moonshot.

Interested investigators are encouraged to sign up to receive automatic updates from NCI on opportunities associated with the Cancer Moonshot as they become available. 

Feature1
Exploring the Role of Body Composition in Cancer Outcomes

Obesity is an established risk factor for cancer incidence, yet studies suggest that overweight and obese patients (particularly those with a body mass index, or BMI, under 35) may experience improved survival after a cancer diagnosis compared to leaner patients. This "obesity paradox" has been observed for multiple cancer sites, diabetes, kidney disease, heart disease, and overall mortality. While this association could result from selection bias or confounding in analysis, it is also possible that some aspect of increased body weight may infer protection for cancer survivors. 

Body composition is particularly important for cancer survivors, as sarcopenia (low muscle mass) and obesity (excess adipose tissue) have been associated with increased chemotherapy toxicity, poorer surgical outcomes, and shorter survival. Some estimates suggest almost half of cancer survivors are sarcopenic, defined by low muscle mass and/or poor function, which is more than three times higher than a similarly-aged general population. Sarcopenia has been shown as an independent predictor of mortality after adjusting for BMI and other factors; suggesting muscle (body composition) plays an important role that can help explain cancer survival beyond measures of weight and height alone. 

Sarcopenia meeting banner

On September 25-26, 2017, NCI's Epidemiology and Genomics Research Program (EGRP) will host " Understanding the Role of Muscle and Body Composition in Studies of Cancer Risk and Prognosis in Cancer Survivors ," in Rockville, Maryland. This workshop will highlight the growing evidence examining how composition informs the understanding of cancer-related outcomes. It will also identify key methodological challenges and approaches to optimize measurement and analysis, building on past examples studying sarcopenia, cachexia, and frailty in aging populations, and identify the research needed to inform recommendations for cancer survivors. Speakers will include basic researchers, clinicians, epidemiologists, and exercise scientists with expertise in cachexia, aging, muscle and adipose physiology, nutrition, energy balance, metabolism, inflammation, imaging, patient rehabilitation, and more. Interested individuals are invited to attend in person or via webinar.

For more information about the workshop, including the complete agenda and information on registering, visit the workshop web page. Questions about this event should be sent to Joanne Elena, Ph.D., M.P.H.

Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute | 9609 Medical Center Drive | 4 East, MSC 9763 | Bethesda | MD 20892


Contact Us Privacy Policy | Accessibility | FOIA

U.S. Department of Health and Human Services
National Institutes of Health | National Cancer Institute | USA.gov